| 1.36 -0.15 (-9.93%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.05 |
1-year : | 2.33 |
| Resists | First : | 1.75 |
Second : | 2 |
| Pivot price | 1.79 |
|||
| Supports | First : | 1.36 |
Second : | 1.13 |
| MAs | MA(5) : | 1.56 |
MA(20) : | 1.81 |
| MA(100) : | 7.88 |
MA(250) : | 10.32 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5  |
| %K %D | K(14,3) : | 0.3 |
D(3) : | 3 |
| RSI | RSI(14): 22.1 |
|||
| 52-week | High : | 19.39 | Low : | 1.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TENX ] has closed below the lower bollinger band by 8.2%. Bollinger Bands are 85.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 34 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.49 - 1.51 | 1.51 - 1.52 |
| Low: | 1.33 - 1.35 | 1.35 - 1.36 |
| Close: | 1.34 - 1.37 | 1.37 - 1.39 |
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Thu, 15 Oct 2026
Three parties each report 1.36M shares of Tenax Therapeutics (TENX). - Stock Titan
Thu, 15 Oct 2026
SPHERA FUNDS MANAGEMENT LTD. Boosts Tenax Therapeutics Inc (TENX) Stake with 669,800-Share Purchase - GuruFocus
Tue, 13 Oct 2026
TENX Stock Drifts Lower As Traders Eye Cash Runway - StocksToTrade
Tue, 13 Oct 2026
TENX Stock Drifts Lower As Traders Watch Tight Range - Timothy Sykes
Thu, 08 Oct 2026
Tenax Therapeutics pauses LEVEL-2 enrollment to implement enrichment after Phase 3 LEVEL learnings - TradingView
Fri, 02 Oct 2026
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 37 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 108.2 (%) |
| Shares Short | 7,180 (K) |
| Shares Short P.Month | 9,280 (K) |
| EPS | -1.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.8 % |
| Return on Equity (ttm) | -59.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -46 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -0.92 |
| PEG Ratio | 1.4 |
| Price to Book value | 0.62 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|